Almac Wins News Flow of the Year Category at the Genesis 2010 Awards

By Almac Group, PRNE
Wednesday, December 15, 2010

Accolade Recognises Strong Communication of Almac's Integrated Services and US Expansion Programmes

CRAIGAVON, Northern Ireland, December 16, 2010 - The Almac Group, one of the world's leading contract drug development and
manufacturing organisations, was presented with the "News Flow of the Year"
accolade at the 2010 Genesis Awards annual Gala dinner in London last week,
following the company being shortlisted as a finalist in the category
nominations. Now into its tenth year, Genesis is established as a leading
life science networking conference.

Recognised by the Genesis Awards panel as an "ambassador for the UK life
sciences sector", Almac's 2010 news flow has increased exponentially compared
to previous years. Messaging and announcements have been tailored to
developments within the Group's areas of expertise, which extend from
research, through development to commercialisation. Over 35 new stories have
already been released this year with well over 400 items of coverage secured
in target trade media world-wide.

The award comes hot on the heels of a string of accolades won by Almac
this year, including winning the excellence in 'Innovation' category at
Northern Ireland's tenth annual Belfast Telegraph Business Awards in
recognition of the Group's discovery and validation of new pioneering
biomarkers in the field of personalised medicine. Moreover, Almac was rated
Great Place to Work(R), complete with a top five company 'excellence in
disability' rating, by the Great Place to Work(R) Institute UK'.

De Facto Communications, the leading life science and healthcare
communications agency, implemented a news flow communications strategy for
the organisation that focused on aligning Almac's internal proposition with
external perceptions across the wider market and industry. Furthermore, the
Group's US expansion has been extensively covered in announcements and
secured media exposure. This approach has enabled Almac to showcase its wider
integrated offerings to a more diverse range of audiences, highlighting the
Company's size, history and corporate strengths.

Tristan Jervis, Associate Director at De Facto Communications, commented:
"To achieve these communications goals, a series of messaging meetings were
arranged within the Group at the start of 2010. Targeted media lists and
multiple expertise marketing communications plans were created, together with
a Group-wide communications plan, specifically designed to capture central
corporate messages. This innovative approach has enabled the company to
produce a constant stream of highly targeted coverage, whilst enabling Almac
to more closely mirror its internal structure externally."

Philip Diamond, Vice President of Corporate Market Development at the
Almac Group, commented: "We are very pleased to have won this prestigious
accolade and for the recognition that it affords. Indeed, we have
significantly increased the volume of news flow released to the media this
year and thanks to the quality of these announcements, we have significantly
expanded our profile in the life science and pharmaceuticals sectors whilst
enhancing target audience awareness of our integrated service offering and
the expansion of our US operations."

Alan Armstrong, CEO of the Almac Group, commented: "In addition to an
extensive and regular flow of business related press releases, we have also
focused announcements on CSR programmes, especially our regional support
initiatives. Highlights have included a focus on Almac's history, roots and
committed support for the local Northern Ireland economy; exemplified by our
late founder, Sir Allen McClay, being honoured with Craigavon's "Young
Business Person of the Year" Award named after him, together with the opening
of the new Queen's University library that he privately funded."

About Almac Group:

The Almac Group offers a broad range of services from R&D, biomarker
discovery and development, API manufacture, formulation development, clinical
trial supply and IXRS technology (IVRS/IWRS), to commercial-scale
manufacture. Almac provides services to more than 600 companies, including
all the world leaders in the pharmaceutical and biotech sectors.

The company employs almost 3,000 individuals and is headquartered in
Craigavon, Northern Ireland. US operations are based in Pennsylvania, North
Carolina
and California. Almac has officially gained full possession of its
new $120m North American Headquarters which started in July 2008 and
employees are relocating during the fall.

For more information about the Almac Group, please visit
www.almacgroup.com

For further information contact: Tristan Jervis, Associate Director, De Facto Communications, 330 High Holborn, London WC1V 7QD, T: +44(0)207-861-3838, E: t.jervis at defacto.com, e-mail info at almacgroup.com

YOUR VIEW POINT
NAME : (REQUIRED)
MAIL : (REQUIRED)
will not be displayed
WEBSITE : (OPTIONAL)
YOUR
COMMENT :